Phibro Animal Health (PAHC) Declares $0.10 Quarterly Dividend; 1.2% Yield

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. SAP
6. MRNA
7. CSX
8. WDC
9. LVS
10. NDAQ

Go back to Phibro Animal Health (PAHC) Declares $0.10 Quarterly Dividend; 1.2% Yield

Phibro Animal Health Corporation Declares Quarterly Dividend

November 9, 2015 4:47 PM EST

TEANECK, N.J., Nov. 09, 2015 (GLOBE NEWSWIRE) -- The Board of Directors of Phibro Animal Health Corporation (Nasdaq: PAHC) today declared a quarterly cash dividend of $0.10 per share on its Class A common stock and Class B common stock, payable on December 23, 2015, to... More

Phibro Animal Health Corporation Declares Quarterly Dividend

November 9, 2015 4:47 PM EST

TEANECK, N.J., Nov. 09, 2015 (GLOBE NEWSWIRE) -- The Board of Directors of Phibro Animal Health Corporation (Nasdaq: PAHC) today declared a quarterly cash dividend of $0.10 per share on its Class A common stock and Class B common stock, payable on December 23, 2015, to... More

Phibro Animal Health Corporation Reports First Quarter

November 9, 2015 4:45 PM EST

TEANECK, N.J., Nov. 09, 2015 (GLOBE NEWSWIRE) -- Phibro Animal Health Corporation (NASDAQ: PAHC) today announced its financial results for its first quarter ended September 30, 2015.

Highlights for the September 2015 quarter (compared to the September 2014 quarter, excluding the prior year milestone payments for licensing of vaccine delivery technology)

- Net sales of $187 million, an increase of 3%- Adjusted EBITDA of $27.7 million, an increase of 13%- Adjusted diluted EPS of $0.44  compared with $0.36

COMMENTARY  

I am once again proud of the performance of our team.  Despite the economic... More

Phibro Animal Health Corporation Reports First Quarter

November 9, 2015 4:45 PM EST

TEANECK, N.J., Nov. 09, 2015 (GLOBE NEWSWIRE) -- Phibro Animal Health Corporation (NASDAQ: PAHC) today announced its financial results for its first quarter ended September 30, 2015.

Highlights for the September 2015 quarter (compared to the September 2014 quarter, excluding the prior year milestone payments for licensing of vaccine delivery technology)

- Net sales of $187 million, an increase of 3%- Adjusted EBITDA of $27.7 million, an increase of 13%- Adjusted diluted EPS of $0.44  compared with $0.36

COMMENTARY  

I am once again proud of the performance of our team.  Despite the economic... More